Fosmetpantotenate fails in Phase III FORT study to treat pantothenate kinase-associated neurodegeneration

Retrophin, Inc. announced that the Phase III FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration (PKAN) did not meet its primary endpoint and did not demonstrate a difference between treatment groups The study also did not meet its secondary endpoint.

Fosmetpantotenate was observed to be generally safe and well-tolerated in the study.Data from the FORT Study will be further analyzed and are expected to be presented at an upcoming scientific congress, and the Company will be working with study investigators to determine the appropriate next steps for the FORT Study, including the ongoing open-label extension of the study.